Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound B4
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Compound B4 is a novel selenium-containing derivative of flutamide (a Se-flutamide analog) investigated for its potential in treating prostate cancer. It belongs to a series of selenoderivatives designed to improve upon the efficacy of flutamide, particularly against androgen receptor (AR)-independent cell lines. In preclinical studies, Compound B4 demonstrated significant antiproliferative activity against both AR-dependent (LNCaP) and AR-independent (DU-145 and PC-3) prostate cancer cells. Its mechanism of action is primarily linked to androgen receptor antagonism, inherited from its parent compound flutamide, while the selenium moiety likely enhances its ability to induce cell cycle arrest and apoptosis.
- Other names
- Se-flutamide derivative b4
Beyond the preview
Go deeper on Compound B4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound B4.